1Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc), 2003, 39(Suppl C): 1 - 16.
2Mclaughlin P, Cabanillas F, Grillo-Lopez AJ, et al. IDEC-C2B8 anti-CD20 antibody:final report on a phase Ⅲ pivotal trials in patients with relapsed low-grade follicular lymphoma. Blood, 1996,88:90.
3Ghielmini M, Sehmiz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free Survival and response duration compared with the standard weekly x4 schedule. Blood, 2004, 103:4416 - 4423.
4Czuczman MS, Grillo-lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol, 1999, 17:268 - 276.
5Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20Monoclonal Antibody) for the treatment of patients with relapsing or refratory aggressive lymphoma:a multicenter phase Ⅱ study. Blood,1998, 92:1927 - 1932.
6Vase JM, Link BK, Grossbard ML, et al, Phase Ⅱ study of rituximab in combination with CHOP chemotherapy in patients with previously unteated, aggressive non-Hodgkin's lymphoma. J Clin Oncol, 2001,19:389 - 397.
7Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus retuximab compared with CHOP alone in elderly patients 60 years of age and older with diffuse large B cell lymphoma. N Engl J Med, 2002, 346:235 - 242.
8Pfreundschuh MG, Trumper L, Ma D, et al. Randomized integroup trial of first line treament for patients ≤60 years with diffuse large B-cell non-Hodgkin's lymphoma with a CHOP-like regimen with or without the anti-CD20 antibody rituximab-early stopping after the first interim analysis. Proc Asco, 2004, 556a.
9Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle cell lymphoma:molecular complete response are not predictive of progression-free survival. J Clin oncol, 2002, 20:1288 - 1294.
10Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and Small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol, 2001, 19:2153 - 2164.
